Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact
Knowledge Centre
Learn about gastrointestinal conditions.
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis (GP)
Chronic Idiopathic Constipation (CIC)
Irritable Bowel Syndrome (IBS)
GERD (GERD)
Functional Dyspepsia (FD)
Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact